Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

Building a heart: Realheart aims to create new opportunities for patients with heart failure

A mechanical heart, as close to a human heart as it gets. Realheart is the company developing a total artificial heart for patients with advanced heart failure, a condition where treatment options are often limited. When we sit down with CEO Ina Laura Perkins, she tells the story of an innovation that has taken its time, about the strong drive to reach all the way to patients, and about steps that are bringing the company closer to clinical reality.

Summer Breakfast Focused on Collaboration and a Shared Vision for Flemingsberg’s Future

Recently, stakeholders from business, academia, and the public sector gathered for the Summer Breakfast event, “What’s Happening in Flemingsberg?”, to take the pulse of developments in the area.

New Initiative Strengthens Stockholm’s Game Industry – SEK 11.5 Million Invested in the Press Start GameTech Initiative

A total of SEK 11.5 million is now being invested in the development of Press Start GameTech Hub – an initiative aimed at strengthening the GameTech sector in the Stockholm region. The project is led by the Flemingsberg Science Foundation and Södertörn University and will run from September 2026 to 2029.